The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2024 | Importance of subgroup analyses to confirm treatment efficacy across diverse populations
Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, emphasizes the significance of subgroup analyses for hepatobiliary cancers, as they can confirm the efficacy and safety of treatments in a broader population, including those from diverse ethnic and geographic backgrounds, and inform clinical practice. This interview took place at the ESMO Asia Congress 2024, held in Singapore, Republic of Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
